These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34568375)

  • 1. A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.
    Lee CC; Wang CY; Hung CC; Huang CC; Li CY; Chen HY; Chang YL; Tseng WJ; Wang TM; Yang RS; Wong TH; Fu SH
    Front Med (Lausanne); 2021; 8():717168. PubMed ID: 34568375
    [No Abstract]   [Full Text] [Related]  

  • 2. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
    Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting.
    Everts-Graber J; Reichenbach S; Gahl B; Häuselmann H; Ziswiler HR; Studer U; Lehmann T
    Bone; 2022 Oct; 163():116498. PubMed ID: 35882310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
    Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
    Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial.
    Prasad TN; Bhadada SK; Singla V; Aggarwal N; Ram S; Saini UC; Kumar A; Pal R
    Ther Adv Endocrinol Metab; 2023; 14():20420188231207516. PubMed ID: 37873516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.
    Everts-Graber J; Lehmann T
    J Clin Densitom; 2022; 25(3):293-298. PubMed ID: 35450795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P
    Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?
    Grassi G; Ghielmetti A; Zampogna M; Chiodini I; Arosio M; Mantovani G; Eller-Vainicher C
    J Clin Endocrinol Metab; 2024 Sep; 109(10):e1817-e1826. PubMed ID: 38609157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One versus 2 years of alendronate following denosumab: the CARD extension.
    Tsai JN; Jordan M; Lee H; Leder BZ
    Osteoporos Int; 2024 Dec; 35(12):2225-2230. PubMed ID: 39112628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.
    Anastasilakis AD; Makras P; Polyzos SA; Papapoulos SE
    Calcif Tissue Int; 2023 Oct; 113(4):469-473. PubMed ID: 37535102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
    Horne AM; Mihov B; Reid IR
    Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Efficacy of Zoledronate and Denosumab in Patients with Acute Osteoporotic Vertebral Compression Fractures: A Randomized Controlled Trial.
    Son S; Oh MY; Yoo BR; Park HB
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.